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Abstract
Psychoactive substances of the 2C‐series are phenethylamine‐based designer drugs
that can induce psychostimulant and hallucinogenic effects. The so‐called 2C‐FLY
series contains rigidified methoxy groups integrated in a 2,3,6,7‐
tetrahydrobenzo[1,2‐b:4,5‐b’]difuran core. The aim of the presented work was to
investigate the in vivo and in vitro metabolic fate including isoenzyme activities and
toxicological detectability of the three new psychoactive substances (NPS) 2C‐E‐
FLY, 2C‐EF‐FLY, and 2C‐T‐7‐FLY to allow clinical and forensic toxicologists the iden-
tification of these novel compounds. Rat urine, after oral administration, and pooled
human liver S9 fraction (pS9) incubations were analyzed by liquid chromatography
−high‐resolution tandem mass spectrometry (LC−HRMS/MS). By performing activity
screenings, the human isoenzymes involved were identified and toxicological detect-
ability in rat urine investigated using standard urine screening approaches (SUSAs)
based on gas chromatography (GC)−MS, LC−MSn, and LC−HRMS/MS. In total, 32
metabolites were tentatively identified. Main metabolic steps consisted of hydroxyl-
ation and N‐acetylation. Phase I metabolic reactions were catalyzed by CYP2D6,
3A4, and FMO3 and N‐acetylation by NAT1 and NAT2. Methoxyamine was used
as a trapping agent for detection of the deaminated metabolite formed by MAO‐A
and B. Interindividual differences in the metabolism of the 2C‐FLY drugs could be
caused by polymorphisms of enzymes involved or drug–drug interactions. All three
SUSAs were shown to be suitable to detect an intake of these NPS but common
metabolites of 2C‐E‐FLY and 2C‐EF‐FLY have to be considered during interpretation
of analytical findings.
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1 | INTRODUCTION
Innumerable new psychoactive substances (NPS) are sold as drugs of
abuse.1,2 NPS are often derivatives of drugs under legislative control
mimicking their psychoactive effects. This is also true for the 2C‐FLY
drugs, which are derived from the well‐known phenethylamines of
the 2C‐type and which are also expected to induce psychostimulant
and hallucinogenic effects. Chemically, they contain rigidified methoxy
groups integrated in a 2,3,6,7‐tetrahydrobenzo[1,2‐b:4,5‐b’]difuran
core in contrast to the classic 2Cs with two methoxy groups located
in positions 2 and 5 of the phenyl ring. Exposure to NPS can result
in significant health risks as demonstrated by frequent reports on toxic
effects and fatal intoxications.3-7 Therefore, clinical and forensic toxi-
cologists should be able to reliably detect an intake of NPS. Both par-
ent compounds and metabolites can be suitable screening targets in
human biosamples, which are especially important for the develop-
ment of urine screening approaches.8 A prerequisite is knowledge of
their metabolic fate. Furthermore, knowledge of the isoenzymes
involved in the metabolism is important to predict drug–drug/drug
−food interactions and/or individual differences found in half‐life
and excretion patterns.
A series of FLY compounds were originally synthesized to study 5‐
HT2A receptor function and 2‐(4‐bromo‐2,3,6,7‐tetrahydrofuro[2,3‐f]
[1]benzofuran‐8‐yl)ethanamine (2C‐B‐FLY) was shown to potently
bind to the human 5‐HT2A receptor.
9-11 2C‐B‐FLY was first reported
to the early warning system on NPS implemented by the European
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) in
2007 and several times afterwards.12 However, little is known about
the toxicokinetics of 2C‐FLY derivatives. Recently, the four 2C‐FLY
compounds 2C‐B‐FLY, 2‐(4‐ethyl‐2,3,6,7‐tetrahydrofuro[2,3‐f][1]
benzofuran‐8‐yl)ethanamine (2C‐E‐FLY), 2‐(4‐iodo‐2,3,6,7‐
tetrahydrofuro[2,3‐f][1]benzofuran‐8‐yl)ethanamine (2C‐I‐FLY), and
2‐(4‐propylthio‐2,3,6,7‐tetrahydrofuro[2,3‐f][1]benzofuran‐8‐yl)
ethanamine (2C‐T‐7‐FLY) were identified as inhibitors of the mono-
amine oxidase A.13 An in vitro metabolism study of 2C‐B‐FLY was also
published recently,14 but nothing is known about the toxicokinetics of
the other 2C‐FLY compounds.
Therefore, the aim of the presented work was to close this gap by
investigating the in vivo and in vitro metabolic fate of 2C‐E‐FLY, 2‐(4‐
(2‐fluor)ethyl‐2,3,6,7‐tetrahydrofuro[2,3‐f][1]benzofuran‐8‐yl)
ethanamine (2C‐EF‐FLY), and 2C‐T‐7‐FLY (Figure 1) followed by uri-
nary detectability studies and identification of enzymes involved in ini-
tial metabolic steps.
2 | EXPERIMENTAL
2.1 | Chemicals and enzymes
2C‐E‐FLY, 2C‐EF‐FLY, and 2C‐T‐7‐FLY were provided as hydrochlo-
ride salts by Synex Synthetics BV (Maastricht, Netherlands). Isocitrate,
isocitrate dehydrogenase (IDH), superoxide dismutase (SOD), 3′‐
phosphoadenosine‐5′‐phosphosulfate (PAPS), S‐(5′‐adenosyl)‐L‐
methionine (SAM), dithiothreitol (DTT), reduced glutathione (GSH),
acetylcarnitine transferase (AcT), acetylcarnitine, acetyl coenzyme A
(AcCoA), potassium dihydrogenphosphate, dipotassium
hydrogenphosphate, Tris base, triethanolamine (TEA),
ethylendiaminetetraacetic acid, and methoxyamine were obtained
from Sigma‐Aldrich (Taufkirchen, Germany) and NADP+ from Biomol
(Hamburg, Germany). Acetonitrile (ACN, LC–MS grade), ammonium
formate (analytical grade), formic acid (LC–MS grade), methanol (LC–
MS grade), and all other chemicals and reagents (analytical grade) were
obtained from VWR (Darmstadt, Germany).
The baculovirus‐infected insect cell microsomes (Supersomes) con-
taining the human complementary cDNA‐expressed cytochrome P450
(CYP) enzymes CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9,
CYP2C19, CYP2D6, CYP3A4 (1 nmol/mL), or CYP2E1, CYP3A5
(2 nmol/mL), or flavin‐containing monooxygenase 3 (FMO3), MAO‐
A, or MAO‐B (5 mg protein/mL), or wild type Supersomes without
MAO activity as negative control (MAO control, 5 mg protein/mL),
and pooled human liver microsomes (pHLMs, 20 mg microsomal
protein/mL, 330 pmol total CYP/mg protein), pS9 (20 mg microsomal
protein/mL), uridine 5′‐diphospho‐glucuronosyltransferase (UGT)
reaction mixture solution A (25mM UDP‐glucuronic acid), and UGT
reaction mixture solution B (250mM Tris–HCl, 40mM MgCl2, and
0.125 mg/mL alamethicin) were obtained from Corning (Amsterdam,
Netherlands). Supersomes containing human complementary cDNA‐
expressed NAT1 (arylamine NAT1*4, wild‐type allele) and NAT2
(arylamine NAT2*4 wild‐type allele) were obtained from BD Biosci-
ences (Heidelberg, Germany). After delivery, the enzyme preparations
and PAPS were thawed at 37°C, aliquoted, snap‐frozen in liquid nitro-
gen, and stored at −80°C until use.
2.2 | Rat urine samples
As already described in previous studies, the in vivo experiments were
performed using urine samples from male Wistar rats (Charles River,
Sulzfeld, Germany) for toxicological diagnostic reasons according to
German law (“Tierschutzgesetz”, Bundesministerium der Justiz und
für Verbraucherschutz, 2018, dealing with the treatment of laboratory
animals and the experimental design aiming to prevent unnecessary
pain, harm, and distress).15-17 First, blank urines were collected over
a period of 24 hours to verify the absence of interfering compounds.
Afterwards the compounds were administered in an aqueous solution
via gastric intubation as a single dose of 0.2 mg/kg body weight (BW)
for toxicological detectability studies (low dose) and a single dose of
2 mg/kg BW (high dose) for identification of the metabolites and tox-
icological detectability studies. During the collection of urine over aFIGURE 1 Chemical structures of the investigated 2C‐FLY drugs
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period of 24 hours, the rats were housed in metabolism cages and
urine was collected separated from feces. The urine samples were
analyzed directly and remaining samples were aliquoted and stored
at −20°C. One rat was used per NPS.
2.3 | Rat urine sample preparation for identification
of metabolites
2.3.1 | Precipitation
Identification of phase I and II metabolites in rat urine was performed
after urine precipitation (UP) as described elsewhere.18 A volume of
100 μL urine collected after high dose administration was precipitated
with 500 μL acetonitrile. The mixture was vortexed and centrifuged
for 2minutes at 18 407 x g. The supernatant was evaporated to dryness
under a stream of nitrogen. The residue was reconstituted in 50 μL of a
1:1 (v/v) mixture of eluents A and B and transferred to an autosampler
vial. One μL was injected onto the LC−HRMS/MS system.
2.3.2 | Solid‐phase extraction
According to Maurer et al,19 2.5 mL of high dose rat urine was poured
into a centrifugal glass and 2 mL of distilled water and 50 μL of
0.01 mg/mL trimipramine‐d3 as internal standard were added. The
HCX cartridge was conditioned with 1 mL methanol and 1 mL distilled
water before transferring the samples to the cartridge. After the pas-
sage of the sample, the cartridge was washed with 1 mL distilled
water, 1 mL 0.01 M hydrochloric acid, and 2 mL methanol. Thereafter,
compounds of interest were eluted with 1 mL of a mixture of
methanol/aqueous ammonia 33% (98:2, v/v) into an autosampler vial
and evaporated to dryness under a stream of nitrogen at 60°C. The
extract was reconstituted in 50 μL methanol and 1 μL was injected
onto the LC‐HRMS/MS system.
2.4 | pS9 incubations
As described before,20 the final incubation volume was 150 μL and the
final protein concentration was 2 mg/mL. All given concentrations are
final concentrations in the incubation mixture. First, a mixture contain-
ing 25 μg/mL alamethicin (UGT reaction mixture solution B), 90mM
phosphate buffer (pH 7.4), 2.5mM Mg2+, 2.5mM isocitrate, 0.6mM
NADP+, 0.8 U/mL IDH, 100 U/mL SOD, 0.1mM AcCoA, 2.3mM acetyl
carnitine, 8 U/mL AcT, and 2 mg/mL pS9 was preincubated for
10 minutes at 37°C. Afterwards, 2.5mM UDP glucuronic acid (UGT
reaction mix solution A), 40 μM aqueous PAPS, 1.2mM SAM, 1mM
DTT, and 10mM GSH were added. The reactions were started by
addition of 25 μM of one of the 2C‐FLY derivatives in phosphate
buffer and the tube was incubated for 6 hours. After 1 hour, 60 μL
of the incubation mixture was transferred into another tube and the
reaction was terminated by addition of 20 μL ice‐cold acetonitrile.
The remaining mixture (90 μL) was incubated for an additional 5 hours
and then stopped with 30 μL ice‐cold acetonitrile. All solutions were
cooled for 30 minutes at −20°C, centrifuged for 2 minutes at 18 407
x g, and 50 μL of the supernatants were transferred to autosampler
vials. One μL was injected onto the LC−HRMS/MS system. Blank
incubations without 2C‐FLY derivative and control samples without
pS9 were prepared to confirm the absence of interfering compounds
and to identify compounds that are not of metabolic origin. All incuba-
tions were done in duplicate.
2.5 | Isoenzyme activity screenings
2.5.1 | Monooxygenases activity screening
The microsomal incubations were performed at 37°C for 30 minutes
with 25 μM of the 2C‐FLY analog and 50 pmol/mL CYP isoenzyme
(CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4, or 3A5) or
0.25 mg protein/mL FMO3.21 The incubation mixtures with a final vol-
ume of 50 μL also contained 90mM phosphate buffer (pH 7.4), the
NADP+ regenerating system (1.2mM NADP+, 5mM Mg2+, 5mM
isocitrate, 0.5 U/mL IDH), and 200 U/mL SOD. All incubations were
performed with phosphate buffer except for the ones with CYP2A6
and CYP2C9 which were performed with 90mM Tris buffer (pH 7.4).
A positive control with 1 mg protein/mL pHLM and a blank incubation
without enzyme was also performed. The reactions were started by
addition of the NADP+ regenerating system and terminated by addition
of 50 μL of ice‐cold acetonitrile. Afterwards the mixture was centri-
fuged for 5 minutes at 18,407 x g and 50 μL of the supernatant were
transferred to an autosampler vial. One μL was injected onto the LC
−HRMS/MS system. All given concentrations are final concentrations.
2.5.2 | Monoamine oxidases activity screening
The incubations were performed at 37°C for 2 hours at a final incuba-
tion volume of 150 μL containing 25 μM of the 2C‐FLY analog, MAO‐
A or MAO‐B (0.2 mg protein/mL), 90mM phosphate buffer, and
10mM of the aldehyde trapping agent methoxyamine.14 All given con-
centrations were final concentrations and a negative control with
MAO control was also performed. The reactions were started by addi-
tion of the enzyme and terminated with 150 μL ice‐cold acetonitrile.
Afterwards, the mixture was centrifuged for 2 minutes at 18 407 x g
and the supernatant was transferred to an autosampler vial. Five μL
were injected onto the hydrophilic interaction liquid chromatography
(HILIC)−HRMS/MS system.
2.5.3 | N‐Acetyltransferases activity screening
Incubations were performed at 37°C for 30 minutes with 50 μM of
substrate and NAT1 or NAT2 (0.05 mg protein/mL).22,23 Besides sub-
strate and enzyme, the incubation mixture with final volume of 150 μL
also contained buffer at pH 7.5 consisting of 100mM TEA, 500mM
ethylendiaminetetraacetic acid, and 50mM DTT, and the CoA‐system
consisting of 0.1mM AcCoA, 2.3mM acetylcarnitine, and 0.008 U/μL
AcT. First, the incubation mixture was preincubated at 37°C for
10 minutes. Subsequently, the reactions were started by addition of
substrate and terminated after 30 minutes by addition of 50 μL of
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TABLE 1 2C‐E‐FLY, 2C‐EF‐FLY, 2C‐T‐7‐FLY, and their phase I and II metabolites identified in rat urine and/or in vitro incubations by means of LC
−HRMS/MS together with their identification numbers (iDs), metabolic reactions, precursor ion masses (PMs) recorded in MS1, characteristic frag-
ment ions (FIs) in MS2, relative intensities in MS2, calculated exact masses, elemental compositions, deviations of the measured from the calculated
masses, and retention times (RTs)
Metabolite
iD
Metabolic
Reaction
Characteristic ions at Measured
Accurate Masses, m/z
Relative
Intensity in
MS2, %
Calculated Exact
Masses, m/z
Elemental
Composition
Error,
ppm
RT,
min
2C‐E‐FLY Parent compound PM at m/z 234.1486 8 234.1488 C14H20O2N −0.76 4.60
FI at m/z 217.1225 100 217.1222 C14H17O2 1.24
FI at m/z 188.0831 13 188.0831 C12H12O2 0.00
FI at m/z 161.0594 2 161.0596 C10H9O2 −1.42
FI at m/z 133.0650 1 133.0647 C9H9O 2.14
M1 Hydroxylation PM at m/z 250.1433 25 250.1437 C14H20O3N −1.57 3.36
FI at m/z 233.1170 100 233.1171 C14H17O3 −0.62
FI at m/z 215.1063 26 215.1066 C14H15O2 −1.30
FI at m/z 190.0986 61 190.0988 C12H14O2 −0.81
FI at m/z 175.0751 8 175.0753 C11H11O2 −1.03
M2 Hydroxylation PM at m/z 250.1435 10 250.1437 C14H20O3N −0.77 3.74
FI at m/z 233.1171 64 233.1171 C14H17O3 0.00
FI at m/z 215.1065 100 215.1066 C14H15O2 −0.37
FI at m/z 203.1065 10 203.1066 C13H15O2 −0.39
FI at m/z 187.1115 42 187.1117 C13H15O −0.88
FI at m/z 159.0802 14 159.0804 C11H11O −1.04
FI at m/z 131.0491 1 131.0491 C9H7O 0.00
M3 Dihydroxylation PM at m/z 266.1392 32 266.1386 C14H20O4N 2.22 2.13
FI at m/z 249.1118 100 249.1121 C14H17O4 −1.04
FI at m/z 218.0934 17 218.0937 C13H14O3 −1.23
FI at m/z 203.1064 27 203.1066 C13H15O2 −0.88
FI at m/z 190.0985 18 190.0988 C12H14O2 −1.34
FI at m/z 175.0752 6 175.0753 C11H11O2 −0.45
M4 Dihydroxylation PM at m/z 266.1386 7 266.1386 C14H20O4N 0.00 2.93
FI at m/z 248.1276 24 248.1280 C14H18O3N −1.79
FI at m/z 230.1172 12 230.1175 C14H16O2N −1.21
FI at m/z 201.0910 100 201.0909 C13H13O2 0.35
FI at m/z 191.1069 1 191.1066 C12H15O2 1.68
FI at m/z 188.0830 5 188.0831 C12H12O2 −0.56
FI at m/z 173.0959 5 173.0960 C12H13O −0.66
FI at m/z 131.0490 1 131.0491 C9H7O −0.76
M5 Dihydroxylation PM at m/z 266.1381 22 266.1386 C14H20O4N −1.91 3.16
FI at m/z 248.1275 36 248.1280 C14H18O3N −2.19
FI at m/z 231.1011 100 231.1015 C14H15O3 −1.71
FI at m/z 213.0905 46 213.0909 C14H13O2 −2.02
FI at m/z 203.1062 18 203.1066 C13H15O2 −1.87
FI at m/z 185.0959 16 185.0960 C13H13O −0.62
FI at m/z 157.0646 4 157.0647 C11H9O −0.73
FI at m/z 131.0500 1 131.0491 C9H7O 6.87
M6 Dihydroxylation PM at m/z 266.1396 23 266.1386 C14H20O4N 3.73 3.78
FI at m/z 249.1119 23 249.1121 C14H17O4 −0.64
FI at m/z 231.1015 29 231.1015 C14H15O3 0.00
FI at m/z 203.1066 100 203.1066 C13H15O2 0.00
FI at m/z 188.0830 3 188.0831 C12H12O2 −0.56
FI at m/z 175.0752 13 175.0753 C11H11O2 −0.45
M7 Trihydroxylation PM at m/z 282.1336 100 282.1335 C14H20O5N 0.27 2.72
FI at m/z 265.1067 57 265.1070 C14H17O5 −1.03
FI at m/z 247.0962 13 247.0964 C14H15O4 −0.85
FI at m/z 229.0861 97 229.0858 C14H13O3 1.12
(Continues)
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TABLE 1 (Continued)
Metabolite
iD
Metabolic
Reaction
Characteristic ions at Measured
Accurate Masses, m/z
Relative
Intensity in
MS2, %
Calculated Exact
Masses, m/z
Elemental
Composition
Error,
ppm
RT,
min
FI at m/z 219.1013 64 219.1015 C13H15O3 −0.89
FI at m/z 203.1063 31 203.1066 C13H15O2 −1.38
FI at m/z 175.0753 175.0753 C11H11O2 0.00
M8 Carboxylation PM at m/z 264.1231 18 264.1230 C14H18O4N 0.92 3.43
FI at m/z 247.0966 100 247.0964 C14H15O4 0.77
FI at m/z 229.0858 1 229.0858 C14H13O3 0.00
FI at m/z 201.0908 63 201.0909 C13H13O2 −0.64
FI at m/z 188.0829 2 188.0831 C12H12O2 −1.09
FI at m/z 173.0959 8 173.0960 C12H13O −0.66
M9 Hydroxylation + O‐glucuronidation PM at m/z 426.1757 16 426.1758 C20H28O9N −0.19 3.32
FI at m/z 250.1434 71 250.1437 C14H20O3N −1.17
FI at m/z 233.1170 100 233.1171 C14H17O3 −0.62
FI at m/z 215.1064 20 215.1066 C14H15O2 −0.84
FI at m/z 187.1115 3 187.1117 C13H15O −0.88
FI at m/z 159.0803 1 159.0804 C11H11O −0.41
M10 N‐acetylation PM at m/z 276.1594 35 276.1593 C16H22O3N 0.20 6.21
FI at m/z 234.1486 5 234.1488 C14H20O2N −0.76
FI at m/z 217.1222 100 217.1222 C14H17O2 0.00
FI at m/z 188.0830 16 188.0831 C12H12O2 −0.56
FI at m/z 161.0596 3 161.0596 C10H9O2 0.00
M11 N‐acetylation + hydroxylation PM at m/z 292.1542 92 292.1543 C16H22O4N −0.20 4.65
FI at m/z 274.1435 12 274.1437 C16H20O3N −0.71
FI at m/z 250.1437 16 250.1437 C14H20O3N 0.00
FI at m/z 233.1172 100 233.1171 C14H17O3 0.24
FI at m/z 215.1066 93 215.1066 C14H15O2 0.00
FI at m/z 203.1068 11 203.1066 C13H15O2 1.08
FI at m/z 187.1115 9 187.1117 C13H15O −0.88
FI at m/z 159.0804 5 159.0804 C11H11O 0.00
M12 N‐acetylation + dihydroxylation PM at m/z 308.1501 27 308.1492 C16H22O5N 3.01 4.63
FI at m/z 290.1385 82 290.1386 C16H20O4N −0.37
FI at m/z 272.1279 1 272.1280 C14H20O3N −0.53
FI at m/z 248.1278 100 248.1280 C14H18O3N −0.98
FI at m/z 231.1012 80 231.1015 C14H15O3 −1.27
FI at m/z 213.0908 1 213.0909 C14H13O2 −0.61
FI at m/z 203.1065 12 203.1066 C13H15O2 −0.39
FI at m/z 185.0960 1 185.0960 C13H13O 0.00
M13 Methoxyamine adduct PM at m/z 262.1437 7 262.1437 C15H20O3N 0.00 1.21
FI at m/z 203.1068 100 203.1066 C13H15O2 1.08
FI at m/z 190.0987 30 190.0988 C12H14O2 −0.29
FI at m/z 175.0754 7 175.0753 C11H11O2 0.69
2C‐EF‐FLY Parent compound PM at m/z 252.1394 15 252.1394 C14H19O2NF 0.00 4.44
FI at m/z 235.1129 100 235.1128 C14H16O2F 0.39
FI at m/z 207.0815 5 207.0815 C12H12O2F 0.00
FI at m/z 188.0831 5 188.0831 C12H12O2 0.00
FI at m/z 159.0805 3 159.0804 C11H11O 0.85
FI at m/z 131.0856 1 131.0855 C10H11 1.14
M1 Oxidative defluorination PM at m/z 250.1433 25 250.1437 C14H20O3N −1.57 3.36
FI at m/z 233.1170 100 233.1171 C14H17O3 −0.62
FI at m/z 215.1063 26 215.1066 C14H15O2 −1.30
FI at m/z 190.0986 61 190.0988 C12H14O2 −0.81
FI at m/z 175.0751 8 175.0753 C11H11O2 −1.03
M14 Hydroxylation PM at m/z 268.1340 39 268.1343 C14H19O3NF −1.01 3.21
(Continues)
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TABLE 1 (Continued)
Metabolite
iD
Metabolic
Reaction
Characteristic ions at Measured
Accurate Masses, m/z
Relative
Intensity in
MS2, %
Calculated Exact
Masses, m/z
Elemental
Composition
Error,
ppm
RT,
min
FI at m/z 251.1074 100 251.1077 C14H16O3F −1.28
FI at m/z 233.0969 1 233.0972 C14H14O2F −1.11
FI at m/z 213.0907 2 213.0909 C14H13O2 −1.08
FI at m/z 190.0985 18 190.0988 C12H14O2 −1.34
M15 Hydroxylation PM at m/z 268.1339 1 268.1343 C14H19O3NF −1.39 3.38
FI at m/z 250.1234 46 250.1237 C14H17O2NF −1.23
FI at m/z 233.0968 100 233.0972 C14H14O2F −1.54
FI at m/z 221.0969 11 221.0972 C13H14O2F −1.17
FI at m/z 205.1021 21 205.1022 C13H14OF −0.70
FI at m/z 185.0958 8 185.0960 C13H13O −1.16
FI at m/z 158.0723 4 158.0725 C11H10O −1.52
M16 Dihydroxylation PM at m/z 284.1287 22 284.1292 C14H19O4NF −1.71 2.75
FI at m/z 266.1181 68 266.1186 C14H17O3NF −1.96
FI at m/z 248.1079 100 248.1081 C14H15O2NF −0.63
FI at m/z 231.0811 62 231.0815 C14H12O2F −1.76
FI at m/z 217.0856 39 217.0858 C13H13O3 −1.13
FI at m/z 199.0753 29 199.0753 C13H11O2 0.00
FI at m/z 189.0910 1 189.0909 C12H13O2 0.37
FI at m/z 183.0804 8 183.0804 C13H11O 0.00
M17 Dihydroxylation PM at m/z 284.1290 48 284.1292 C14H19O4NF −0.66 3.13
FI at m/z 266.1183 12 266.1186 C14H17O3NF −1.21
FI at m/z 249.0917 65 249.0921 C14H14O3F −1.50
FI at m/z 231.0816 50 231.0815 C14H12O2F 0.40
FI at m/z 221.0970 100 221.0972 C13H14O2F −0.71
FI at m/z 203.0864 39 203.0866 C13H12OF −0.95
M8 Oxidative defluorination + oxidation to
carboxylic acid
PM at m/z 264.1228 21 264.1230 C14H18O4N −0.60 3.43
FI at m/z 247.0966 100 247.0964 C14H15O4 0.77
FI at m/z 229.0856 2 229.0858 C14H13O3 −1.07
FI at m/z 201.0907 65 201.0909 C13H13O2 −1.14
FI at m/z 173.0959 8 173.0960 C12H13O −0.66
FI at m/z 145.1010 2 145.1011 C11H13 −0.69
M18 N‐acetylation PM at m/z 294.1495 51 294.1499 C16H21O3NF −1.43 5.79
FI at m/z 252.1394 14 252.1394 C14H19O2NF 0.00
FI at m/z 235.1128 100 235.1128 C14H16O2F 0.00
FI at m/z 207.0815 6 207.0815 C12H12O2F 0.00
FI at m/z 188.0830 8 188.0831 C12H12O2 −0.56
FI at m/z 159.0804 4 159.0804 C11H11O 0.00
M19 Methoxyamine adduct PM at m/z 280.1336 9 280.1343 C15H19O3NF −0.61 1.23
FI at m/z 221.0972 100 221.0972 C13H14O2F 0.00
FI at m/z 208.0894 19 208.0893 C12H13O2F 0.32
FI at m/z 188.0831 1 188.0831 C12H12O2 0.00
2C‐T‐7‐
FLY
Parent compound PM at m/z 280.1359 10 280.1365 C15H22O2NS −2.14 5.29
FI at m/z 263.1095 100 263.1099 C15H19O2S −1.71
FI at m/z 221.0627 26 221.0630 C12H13O2S −1.36
FI at m/z 188.0827 12 188.0831 C12H12O2 −2.15
FI at m/z 159.0801 2 159.0804 C11H11O −1.67
FI at m/z 131.0854 1 131.0855 C10H11 −0.38
M20 Oxidation to sulfoxide PM at m/z 296.1309 88 296.1314 C15H22O3NS −1.06 3.80
FI at m/z 279.1041 14 279.1049 C15H19O3S −2.74
FI at m/z 237.0575 100 237.0579 C12H13O3S −1.33
(Continues)
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TABLE 1 (Continued)
Metabolite
iD
Metabolic
Reaction
Characteristic ions at Measured
Accurate Masses, m/z
Relative
Intensity in
MS2, %
Calculated Exact
Masses, m/z
Elemental
Composition
Error,
ppm
RT,
min
FI at m/z 223.0421 1 223.0423 C11H11O3S −0.74
FI at m/z 219.0471 24 219.0473 C12H11O2S −1.14
FI at m/z 205.0856 35 205.0858 C12H13O3 −1.19
FI at m/z 159.0803 1 159.0804 C11H11O 4.62
FI at m/z 131.0853 1 131.0855 C10H11 −1.15
M21 Hydroxylation PM at m/z 296.1310 4 296.1314 C15H22O3NS −1.40 3.98
FI at m/z 279.1047 100 279.1049 C15H19O3S −0.59
FI at m/z 261.0941 1 261.0943 C15H17O2S −0.77
FI at m/z 221.0628 33 221.0630 C12H13O2S −0.90
FI at m/z 188.0830 10 188.0831 C12H12O2 −0.56
FI at m/z 159.0802 2 159.0804 C11H11O −1.04
FI at m/z 131.0854 1 131.0855 C10H11 −0.38
M22 Oxidation to sulfone PM at m/z 312.1262 70 312.1263 C15H22O4NS −0.73 2.83
FI at m/z 295.0993 9 295.0998 C15H19O4S −1.62
FI at m/z 237.0575 12 237.0579 C12H13O3S −1.75
FI at m/z 223.0422 100 223.0423 C11H11O3S −0.29
FI at m/z 219.0472 9 219.0473 C12H11O2S −0.68
FI at m/z 205.0857 33 205.0858 C12H13O3 −0.70
FI at m/z 188.0830 3 188.0831 C12H12O2 −0.56
FI at m/z 176.0831 27 176.0831 C11H12O2 0.00
FI at m/z 159.0803 2 159.0804 C11H11O −0.41
M23 Dihydroxylation PM at m/z 312.1261 63 312.1263 C15H22O4NS −0.73 3.91
FI at m/z 295.0995 100 295.0998 C15H19O4S −0.95
FI at m/z 253.0526 22 253.0528 C12H13O4S −0.90
FI at m/z 235.0421 11 235.0423 C12H11O3S −0.70
FI at m/z 218.0393 25 218.0395 C12H10O2S −1.03
FI at m/z 207.0473 63 207.0473 C11H11O2S 0.00
FI at m/z 188.0829 1 188.0831 C12H12O2 −1.09
FI at m/z 174.0674 38 174.0675 C11H10O2 −0.31
M24 Carboxylation PM at m/z 310.1104 42 310.1107 C15H20O4NS −0.90 4.00
FI at m/z 293.0840 100 293.0841 C15H17O4S −0.44
FI at m/z 275.0731 1 275.0736 C15H15O2S −1.69
FI at m/z 220.0548 13 220.0552 C12H12O2S −1.70
FI at m/z 188.0829 38 188.0831 C12H12O2 −1.09
FI at m/z 159.0802 4 159.0804 C11H11O −1.04
FI at m/z 131.0853 1 131.0855 C10H11 −1.15
M25 S‐Dealkylation PM at m/z 238.0889 1 238.0895 C12H16O2NS −2.72 4.17
FI at m/z 221.0628 100 221.0630 C12H13O2S −0.90
FI at m/z 188.0830 11 188.0831 C12H12O2 −0.56
FI at m/z 159.0804 1 159.0804 C11H11O 0.00
M26 N‐acetylation PM at m/z 322.1463 42 322.1471 C17H24O3NS −2.37 6.85
FI at m/z 280.1358 4 280.1365 C15H22O2S −2.49
FI at m/z 263.1095 70 263.1099 C15H19O2S −1.71
FI at m/z 247.1198 89 247.1202 C14H17O3S −1.69
FI at m/z 221.0625 26 221.0630 C12H13O2S −2.26
FI at m/z 188.0828 100 188.0831 C12H12O2 −1.62
FI at m/z 159.0798 2 159.0804 C11H11O −3.55
FI at m/z 131.0853 1 131.0855 C10H11 −1.15
M27 N‐acetylation + oxidation to sulfoxide PM at m/z 338.1411 100 338.1420 C17H24O4NS −2.60 5.21
FI at m/z 296.1306 6 296.1314 C15H22O3NS −2.75
FI at m/z 279.1042 5 279.1049 C15H19O3S −2.38
FI at m/z 236.0496 35 236.0501 C12H12O3S −2.07
FI at m/z 219.0467 48 219.0473 C12H11O2S −2.97
(Continues)
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ice‐cold acetonitrile. The mixture was centrifuged for 5 minutes at 18
407 x g and 50 μL of the supernatant was transferred to an
autosampler vial. One μL was injected onto the LC−HRMS/MS
system.
2.6 | LC−HRMS/MS conditions
Analyses were performed using a Thermo Fisher scientific (TF,
Dreieich, Germany) Dionex UltiMate 3000 Rapid Separation (RS)
UHPLC system with a quaternary UltiMate 3000 RS pump and an Ulti-
Mate 3000 RS autosampler controlled by theTF Chromeleon software
version 6.80. It was coupled to a TF Q‐Exactive Plus, equipped with a
heated electrospray ionization II source (HESI II). The mass spectrom-
eter was mass calibrated before analysis using a Positive Mode Cal
Mix (Supelco, Bellefonte, PA, USA).
For all measurements except the MAO activity screening, the LC
conditions were as follows: TF Accucore PhenylHexyl column
(100 mm x 2.1 mm inside diameter, ID, 2.6 μm particle size); gradient
elution with eluent A (2mM aqueous ammonium formate solution con-
taining 0.1% (v/v) formic acid) and eluent B (ammonium formate solu-
tion with acetonitrile/methanol (50:50, v/v) containing 0.1% (v/v)
formic acid and 1% (v/v) water). The gradient was set as follows: 0–
1 minute 1% B, 1–10 minutes to 99% B, 10–11.5 minutes hold 99%
B, 11.5–13.5 minutes hold 1% B. The flow rate settings were as
follows: 0–11.5 minutes at 0.500 mL/min, and 11.5–13.5 minutes at
0.800 mL/min.24
Conditions for the MAO activity screenings were as follows:
Macherey‐Nagel (Düren, Germany) HILIC Nucleodur column
(125 mm x 3 mm ID, 3 μm particle size). As mobile phases eluent
C (200mM aqueous ammonium acetate) and eluent D (acetonitrile
containing 0.1%, v/v, formic acid) were used. The gradient was set
as follows: 0–8.5 minutes 98% D to 40% D, 8.5–10 minutes hold
40% D, 10–12 min hold 98% D. The flow rate was set to
0.500 mL/min.
The HESI‐II conditions were as follows: Heater temperature,
320°C; ion transfer capillary temperature, 320°C; sheath gas, 60 arbi-
trary units (AU); auxiliary gas, 10 AU; spray voltage, 4.00 kV, positive
mode; S‐lens RF level, 50.0. Mass spectrometry was performed in pos-
itive electrospray ionization (ESI) full‐scan mode and targeted MS2
mode with an inclusion list containing masses of expected metabolites.
The settings for full‐scan data acquisition were chosen as follows: res-
olution, 35 000; automatic gain control (AGC) target, 1e6; maximum
injection time (IT), 120 ms; scan range, m/z 200–1200 (2C‐E‐FLY),
m/z 200–1100 (2C‐EF‐FLY), or m/z 200–800 (2C‐T‐7‐FLY). The set-
tings for the targeted MS2 mode were chosen as follows: resolution,
17,500; AGC target, 2e5; maximum IT, 250 ms; isolation window,
m/z 1.0; stepped normalized collision energy (NCE) with steps
17.5%, 35%, 52.5%; pick others, enabled. For data evaluation, TF
Xcalibur Qual Browser software version 2.2 SP 1.48 was used.
TABLE 1 (Continued)
Metabolite
iD
Metabolic
Reaction
Characteristic ions at Measured
Accurate Masses, m/z
Relative
Intensity in
MS2, %
Calculated Exact
Masses, m/z
Elemental
Composition
Error,
ppm
RT,
min
FI at m/z 205.0855 2 205.0858 C11H13O3 −1.68
FI at m/z 188.0827 12 188.0831 C12H12O2 −2.15
M28 N‐acetylation + oxidation to sulfone PM at m/z 354.1360 41 354.1369 C17H24O5NS −2.52 4.16
FI at m/z 294.0787 20 294.0794 C14H16O4NS −2.31
FI at m/z 276.0681 1 276.0688 C14H14O3NS −2.58
FI at m/z 247.1199 28 247.1202 C14H17O3N −1.29
FI at m/z 235.0418 100 235.0423 C12H11O3S −1.97
FI at m/z 219.0468 13 219.0473 C12H11O2S −2.51
FI at m/z 217.0314 26 217.0317 C12H9O2S −1.38
FI at m/z 205.0313 3 205.0317 C11H9O2S −1.95
FI at m/z 188.0829 34 188.0831 C12H12O2 −1.09
FI at m/z 186.0671 20 186.0675 C12H10O2 −1.91
M29 N‐acetylation + carboxylation PM at m/z 352.1200 39 352.1212 C17H22O5NS −3.53 5.34
FI at m/z 334.1095 100 334.1107 C17H20O4NS −3.53
FI at m/z 310.1094 1 310.1107 C15H20O4NS −4.12
FI at m/z 293.0830 22 293.0841 C15H17O4S −3.85
FI at m/z 275.0728 25 275.0736 C15H15O3S −2.42
FI at m/z 247.1194 32 247.1202 C14H17O3N −3.31
FI at m/z 233.0624 13 233.0630 C13H13O2S −2.57
FI at m/z 219.0470 56 219.0473 C12H11O2S −1.60
FI at m/z 188.0826 94 188.0831 C12H12O2 −2.68
M30 Methoxyamine adduct PM at m/z 308.1311 10 308.1314 C16H22O3NS −1.02 1.19
FI at m/z 249.0944 100 249.0943 C14H17O2S 0.40
FI at m/z 236.0862 30 236.0865 C13H16O2S −1.16
FI at m/z 207.0473 29 207.0473 C11H11O2S 0.00
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2.7 | Toxicological detectability in rat urine
Standard urine screening approaches (SUSAs) by gas chromatography
(GC)‐MS, LC‐ion trap (IT)‐MS, and LC‐HRMS/MS were performed as
described before.16,18,19,24 Briefly, urine precipitation with acetonitrile
was performed for the LC‐based SUSAs and liquid–liquid extraction
(LLE) after acidic hydrolysis followed by acetylation for the GC–
MS SUSA.
3 | RESULTS AND DISCUSSION
3.1 | Identification of metabolites
For identification of metabolites, MS1 data after analysis of the in vivo
and in vitro samples were screened for exact precursor masses (PMs)
of expected metabolites. A maximum deviation of 5 ppm betweenmea-
sured and calculated exact PM was accepted. Afterwards, the
TABLE 2 Absolute peak areas of 2C‐E‐FLY, 2C‐EF‐FLY, 2C‐T‐7‐FLY, and their phase I and II metabolites in MS1 derived from analyses of rat
urine samples after urine precipitation (UP) or solid‐phase extraction (SPE) or pS9 incubations by LC−HRMS/MS. metabolite iDs correspond to
Table 1. ‐, not detected
Metabolite
iD Metabolic Reaction
Calculated
Exact
Masses,
m/z
Rat pS9
UP SPE 1 h 6 h
2C‐E‐FLY Parent compound 234.1488 2.35E+07 5.23E+08 1.11E+09 1.27E+09
M1 Hydroxylation 250.1437 1.23E+08 1.39E+09 ‐ ‐
M2 Hydroxylation 250.1437 2.19E+08 3.17E+08 9.14E+05 1.87E+06
M3 Dihydroxylation 266.1386 4.45E+06 4.84E+07 ‐ ‐
M4 Dihydroxylation 266.1386 5.51E+07 4.59E+07 ‐ ‐
M5 Dihydroxylation 266.1386 5.61E+07 2.12E+08 ‐ ‐
M6 Dihydroxylation 266.1386 1.19E+06 1.97E+07 ‐ ‐
M7 Trihydroxylation 282.1335 9.13E+06 ‐ ‐ ‐
M8 Carboxylation 264.1230 1.32E+07 1.30E+08 ‐ ‐
M9 Hydroxylation + O‐glucuronidation 426.1758 7.09E+06 ‐ ‐ ‐
M10 N‐acetylation 276.1593 1.91E+07 7.17E+05 1.52E+07 8.40E+07
M11 N‐acetylation + hydroxylation 292.1543 6.20E+07 ‐ ‐ ‐
M12 N‐acetylation + dihydroxylation 308.1492 4.37E+06 ‐ ‐ ‐
2C‐EF‐FLY Parent compound 252.1394 7.62E+07 1.00E+09 6.23E+08 1.38E+09
M1 Oxidative defluorination 250.1437 1.65E+07 6.68E+07 ‐ ‐
M14 Hydroxylation 268.1343 ‐ 1.11E+08 ‐ ‐
M15 Hydroxylation 268.1343 1.78E+08 5.41E+08 ‐ ‐
M16 Dihydroxylation 284.1292 2.72E+07 6.39E+07
M17 Dihydroxylation 284.1292 5.93E+06 2.32E+07 ‐ ‐
M8 Oxidative defluorination + oxidation to carboxylic acid 264.1230 1.54E+07 6.11E+07 ‐ ‐
M18 N‐acetylation 294.1499 1.03E+07 7.00E+05 3.52E+06 4.29E+07
2C‐T‐7‐FLY Parent compound 280.1365 5.19E+07 5.23E+08 5.54E+08 5.15E+08
M20 Oxidation to sulfoxide 296.1314 3.12E+07 2.98E+08 7.16E+05 1.96E+06
M21 Hydroxylation 296.1314 6.24E+07 7.12E+08 7.37E+05 2.11E+06
M22 Oxidation to sulfone 312.1263 7.46E+06 8.29E+07 ‐ ‐
M23 Dihydroxylation 312.1263 ‐ 1.41E+07 ‐ ‐
M24 Carboxylation 310.1107 2.63E+07 1.98E+08 ‐ ‐
M25 S‐Dealkylation 238.0895 ‐ ‐ ‐ ‐
M26 N‐acetylation 322.1471 ‐ 8.59E+05 1.19E+07 4.01E+07
M27 N‐acetylation + oxidation to sulfoxide 338.1420 1.71E+08 1.68E+07 9.08E+04 2.28E+06
M28 N‐acetylation + oxidation to sulfone 354.1369 1.31E+09 7.29E+07 ‐ ‐
M29 N‐acetylation + carboxylation 352.1212 2.58E+08 1.11E+07 ‐ ‐
WAGMANN ET AL. 1515
fragmentation patterns in their MS2 spectra were interpreted and
compared to those of the parent compounds. Analytical information
of the parent compounds and all phase I and II metabolites are listed
inTables 1 and 2. The given masses are the calculated exact masses. In
total, the analyses of rat urine and in vitro incubations resulted in
detections of several tentative metabolites: 2C‐E‐FLY, 13 metabolites;
2C‐EF‐FLY, 8 metabolites; and 2C‐T‐7‐FLY, 11 metabolites. The
resulting metabolic pathways can be found in Figures 2–4.
Fragmentation patterns of 2C‐E‐FLY and its metabolites are
discussed exemplarily in the following as data of 2C‐EF‐FLY, 2C‐T‐7‐
FLY, and their metabolites were comparable. The MS2 spectrum of
the parent compound 2C‐E‐FLY (M + H+, PM at m/z 234.1488,
C14H20O2N) showed an initial loss of ammonia (−17 u, NH3, fragment
ion, FI at m/z 217.1222, C14H17O2). Afterwards, an ethyl moiety was
eliminated (−29 u, C2H5, FI at m/z 188.0831, C12H12O2). The FI at
m/z 161.0596 (C10H9O2) represented the intact 2,3,6,7‐
tetrahydrobenzo[1,2‐b:4,5‐b’]difuran core before cleavage of one of
the tetrahydrofuran rings with only a methyl group remaining at the
benzene ring (FI at m/z 133.0647, C9H9O). The hydroxy metabolites
(M1 and 2) also showed the loss of ammonia (FI at m/z 233.1171,
C14H17O3) and afterwards an elimination of water (−18 u, H2O)
resulting in a shift of 2 u from FI at m/z 217.1222 (2C‐E‐FLY) to
215.1066 (M1 and 2, C14H15O2). For M1, the position of the hydroxy
group was considered outside the 2,3,6,7‐tetrahydrobenzo[1,2‐b:4,5‐
b’]difuran core. The double bond at the ethyl moiety formed after loss
of water was afterwards eliminated resulting in the two FI at m/z
190.0988 (C12H14O2) and 175.0753 (C11H11O2) representing an
unchanged 2,3,6,7‐tetrahydrobenzo[1,2‐b:4,5‐b’]difuran core with a
remaining ethyl and methyl moiety, respectively. It is likely, that the
hydroxy group was located at the terminal carbon atom of the ethyl
moiety because the corresponding carboxy metabolite (M8) was also
identified. In contrast to M1, M2 was probably hydroxylated at the
2,3,6,7‐tetrahydrobenzo[1,2‐b:4,5‐b’]difuran core due to the FI at
m/z 131.0491 (C9H7O), which had an additional double bond in com-
parison to the FI at m/z 133.0647 (2C‐E‐FLY). The FI at m/z 215.1066
(C14H15O2), 187.1117 (C13H15O), and 159.0804 (C11H11O) also pro-
vided a double bond inside of the ring system. However, exact posi-
tions of the hydroxy groups could not be identified based on
fragmentation patterns.
Four dihydroxy metabolites (M3–M6) could be identified. For M3,
the hydroxy groups were located at the ethyl moiety and the ethyl
amine part as confirmed by the FI 175.0753 (C11H11O2) with an
unchanged 2,3,6,7‐tetrahydrobenzo[1,2‐b:4,5‐b’]difuran core. M4 and
M5 most probably had one of their hydroxy groups at the 2,3,6,7‐
tetrahydrobenzo[1,2‐b:4,5‐b’]difuran core due to the FI at m/z
131.0491 in accordance to M2. M5 was thought to also contain a
hydroxy group at the ethyl moiety and represented therefore a combi-
nation of M1 and M2. In the case of M6, both hydroxylations are
FIGURE 2 Metabolic pathways of 2C‐E‐FLY
detected in rat urine or in in vitro incubations
with pooled human liver S9 fraction (pS9),
pooled human liver microsomes (pHLMs), or
recombinant human monoamine oxidases
(MAOs)
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determined to be located at the ethyl moiety. Again, initial steps were
loss of ammonia and water, followed by the elimination of CO (−28 u
from the FI at m/z 231.1015 (C14H15O3) leading to the FI at m/z
203.1066 (C13H15O2). Furthermore, the presence of FI at m/z
175.0753 (C11H11O2) indicated an unchanged 2,3,6,7‐
tetrahydrobenzo[1,2‐b:4,5‐b’]difuran core. One trihydroxy metabolite
(M7) could also be identified. The absence of a hydroxy group at the
2,3,6,7‐tetrahydrobenzo[1,2‐b:4,5‐b’]difuran core was confirmed by
the FI at m/z 175.0753 (C11H11O2). According to Niessen et al, the car-
boxylic acid, such as that one found in the carboxy metabolite (M8), can
be eliminated in two steps.25 After initial loss of the ammonia (FI at m/z
247.0964, C14H15O4), the elimination ofwater (−18u,H2O) led to the FI
atm/z 229.0858 (C14H13O3) followed by a rearrangement of the double
bonds resulting in the formation of an oxonium ion. Subsequently, CO
was eliminated and led to the FI at m/z 201.0909 (C13H13O2). It should
be considered, that M1 and M8 can also be formed during metabolic
transformation of 2C‐EF‐FLY after oxidative defluorination. In conclu-
sion, both metabolites are not suitable for unambiguous identification
of an intake of 2C‐E‐FLY or 2C‐EF‐FLY and could lead to an incorrect
interpretation of analytical findings.
Concerning phase II metabolites of 2C‐E‐FLY, one O‐glucuronide
and three N‐acetylated metabolites could be detected (M9–M12).
The fragmentation pattern of the O‐glucuronide (M9, PM at m/z
426.1758, C20H28O9N) was in accordance to the corresponding phase
I metabolite (M2) after elimination of glucuronic acid (−176 u,
C6H8O6). After elimination of the acetyl moiety (−42 u, C2H2O), the
N‐acetyl metabolite (M10, PM at m/z 276.1593, C16H22O3N) pro-
vided the same fragmentation pattern as 2C‐E‐FLY. M2 and M5 were
also found to be N‐acetylated in vivo (M11 + 12). In comparison to the
corresponding phase I metabolites, M11 and M12 provided additional
FI in their MS2 spectrum (M11 at m/z 274.1437, C16H20O3N, and
M12 at m/z 290.1386, C16H20O4N, and m/z 272.1280, C14H20O3N)
formed after elimination of water (−18 u, H2O) before elimination of
the acetyl moiety.
In summary, most metabolites were detected in rat urine after pre-
cipitation and only few metabolites were formed in incubations with
pS9 fraction. This was most probably caused by the different experi-
mental conditions. First of all, pS9 incubations were stopped after a
maximum of 6 hours, while rat urine was collected over a 24‐hour
period. In addition, in vitro experiments have limitations concerning dis-
tribution and excretion leading to simple metabolites formed after few
reaction steps. Last but not least, species differences can be followed
by formation of different metabolites. However, to conclude which
model is most suitable for developing urine screening approaches,
authentic human urine would be needed. An intake by humans in the
framework of a controlled trial would be the gold standard, but is
FIGURE 3 Metabolic pathways of 2C‐EF‐
FLY detected in rat urine or in in vitro
incubations with pooled human liver S9
fraction (pS9), pooled human liver microsomes
(pHLMs), or recombinant human monoamine
oxidases (MAOs)
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FIGURE 4 Metabolic pathways of 2C‐T‐7‐FLY detected in rat urine or in in vitro incubations with pooled human liver S9 fraction (pS9), pooled
human liver microsomes (pHLMs), or recombinant human monoamine oxidases (MAOs)
TABLE 3 General involvement of tested cytochrome P450 (CYP) isoenzymes and flavin‐containing monooxygenase 3 (FMO3) in metabolic
phase I steps. ‐, not detected
Metabolic step 2C‐E‐FLY 2C‐EF‐FLY 2C‐T‐7‐FLY
Hydroxylation (chain) CYP2D6 CYP2D6 CYP2D6
CYP3A4
Hydroxylation (core) CYP2D6 CYP2D6 ‐
Oxidation to sulfoxide ‐ ‐ CYP3A4
FMO3
S‐Dealkylation ‐ ‐ CYP2D6
CYP3A4
TABLE 4 Toxicological detectability of 2C‐E‐FLY, 2C‐EF‐FLY, and 2C‐T‐7‐FLY in rat urine by the GC–MS standard urine screening approach.
BW, body weight; +, detected; −, not detected; AC, acetylated
Compound
Precursor
Ion Mass, m/z
Elemental
Composition
Retention
Index (RI)
Characteristic
Fragment Ions, m/z
Administered Dose, mg/kg BW
0.2 2
2C‐E‐FLY‐M (hydroxy) ‐H2O AC 273 C16H19O3N 2320 199, 214 − +
2C‐EF‐FLY AC 293 C16H20O3NF 2480 221, 234 + +
2C‐EF‐FLY‐M (hydroxy) ‐H2O AC 291 C16H18O3NF 2450 199, 219, 232 + +
2C‐EF‐FLY‐M (dihydroxy) ‐2H2O AC 289 C16H16O3NF 2420 197, 217, 230 + +
2C‐T‐7‐FLY AC 321 C17H23O3NS 2720 207, 219, 249, 262 − +
2C‐T‐7‐FLY‐M (hydroxy) ‐H2O AC 319 C17H21O3NS 2690 205, 247, 260 − +
2C‐T‐7‐FLY‐M (hydroxy) 2 AC 379 C19H25O5NS 2890 101, 218, 260, 320 − +
2C‐T‐7‐FLY‐M (dihydroxy) ‐H2O 2 AC 377 C19H23O5NS 2850 101, 216, 258, 318 − +
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considered as unethical, time consuming, and expensive.26 Neverthe-
less, human biosamples after intake of NPS derived from authentic
cases are sometimes available and should then be used for a compara-
tive study summarizing all metabolites detected in vitro and in vivo.
3.2 | Investigation of isoenzyme activities
3.2.1 | Monooxygenases activity screening
The monooxygenases activity screening was performed to investigate
the impact of ten CYP isoenzymes and FMO3 on phase I metabolism
of the three 2C‐FLY derivatives. Incubations with pHLM were used as
positive control. Results are summarized in Table 3. The side chain
hydroxylation of 2C‐EF‐FLY and 2C‐T‐7‐FLYwas catalyzed byCYP2D6
and additionally by CYP3A4 in case of 2C‐E‐FLY. Hydroxylation of the
2,3,6,7‐tetrahydrobenzo[1,2‐b:4,5‐b’]difuran core of 2C‐E‐FLY and
2C‐EF‐FLY was catalyzed by CYP2D6. The thioether moiety of 2C‐T‐
7‐FLY was oxidized to the sulfoxide (M20) by CYP3A4 and FMO3. S‐
Dealkylation of 2C‐T‐7‐FLY (M25) was catalyzed by CYP2D6 and
CYP3A4 and was detected neither in rat urine nor in pS9 incubations.
3.2.2 | Monoamine oxidases activity screening
Due to the primary amine contained in the structure of the 2C‐FLY
drugs, a deamination catalyzed by MAO isoforms was likely to occur
and this metabolic step was already described for 2C compounds.14,27
However, due to the loss of nitrogen, neither the detection of the
deaminated metabolite nor the expected end‐products (oxidized car-
boxylic acid or reduced alcohol) was possible with the used settings.
Therefore, incubations with MAO‐A or B and the aldehyde trapping
agent methoxyamine were performed. The deaminated metabolites
(M13, 19, 30) could afterwards be detected as oxime adducts of the
2C‐FLY drugs and methoxyamine. For M13 (PM at m/z 262.1437,
C15H20O3N), the oxime moiety plus one carbon atom was eliminated
resulting in FI at m/z 203.1066 (C13H15O2) in the first fragmentation
step. Afterwards, the ethyl moiety was eliminated in subsequent steps
(FI at m/z 190.0988, C12H14O2, and 175.0753, C11H11O2). The deam-
ination of all three 2C‐FLY derivatives was found to be catalyzed by
MAO‐A and B. Further kinetic studies would allow to assess, which
isoenzyme is the main catalyzing isoform.
3.2.3 | N‐Acetyltransferases activity screening
N‐Acetylation of the primary amines was found to be one of the main
metabolic steps. In order to investigate which NAT isoenzyme cata-
lyzed this reaction, a NAT activity screening was performed and both
isoforms, NAT1 and NAT2, catalyzed the reaction. Again, further
kinetic studies would allow assessment of which isoenzyme is the
main catalyzing isoform.
3.3 | Toxicological detectability in rat urine
No information concerning dosage of 2C‐E‐FLY, 2C‐EF‐FLY, and 2C‐T‐
7‐FLY in humans could be found but oral 2C‐B‐FLY doses of 10–20 mg
were described.14 This was comparable to 2C‐B dosages of 12–24 mg
as recommended by Shulgin and Shulgin, who also listed dosages of
10–30 mg for 2C‐E and 2C‐T‐7.28 Rat doses of 0.2 (low dose) or
2 mg/kg BW (high dose) corresponded to human doses of 0.03 and
0.33 mg/kg BW, respectively,29 which would be a human oral dose of
2 or 23 mg for a BW of 70 kg. Therefore, recreational doses should be
TABLE 5 Toxicological detectability of 2C‐E‐FLY, 2C‐EF‐FLY, and 2C‐T‐7‐FLY in rat urine by the LC−IT−MS standard urine screening approach.
Precursor ions of the MS3 fragment ions are given in brackets. Metabolite iDs correspond to Table 1. BW, body weight; D, precursor ion in MS1
detected; I, identified due to MS2 spectrum
Metabolite
iD Parent Compound or Metabolite
Precursor
Ion Mass,
m/z
Retention
Time, Min
Characteristic MS2
Fragment Ions at m/z
Characteristic
MS3 Fragment
Ions at m/z
Administered
Dose, mg/kg
BW
0.2 2
Parent
compound
2C‐E‐FLY 234 10.38 217, 189, 188, 171, 161 (189) 161, 133 D I
M1 2C‐E‐FLY‐M (hydroxy) 250 5.94 215, 190, 189, 162 (190) 162, 147, 133 D I
M2 2C‐E‐FLY‐M (hydroxy) 250 6.70 215, 203, 187, 159 (215) 187, 159 I I
M4 2C‐E‐FLY‐M (dihydroxy) 266 4.90 231, 230, 219, 201 (230) 201 D I
M5 2C‐E‐FLY‐M (dihydroxy) 266 5.76 231, 230, 213 (230) 202, 185, 147 D I
M10 2C‐E‐FLY‐M (N‐acetyl) 276 15.32 240, 234, 220, 176, 142, 129 (220) 142, 129 I I
M11 2C‐E‐FLY‐M (N‐acetyl hydroxy) 292 8.49 250, 233, 232, 215 (215) 187, 186, 159 D I
Parent
compound
2C‐EF‐FLY 252 8.69 215, 207, 187, 159 (215) 159 I I
M8 2C‐EF‐FLY‐M (oxidative defluorination and
oxidation)
264 7.45 229, 201, 187, 159, 109 (229) 201, 187 I I
M21 2C‐T‐7‐FLY‐M (hydroxy) 296 7.57 261, 221, 189, 161, 149 (189) 161, 149 I I
M28 2C‐T‐7‐FLY (N‐acetyl sulfone) 354 6.81 294, 247, 235, 188 (247) 188 I I
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expected to be in the range of the high dose, whereas doses resulting in
severe intoxications are expected to be even higher.
3.3.1 | GC–MS SUSA
Results are summarized in Table 4. After low dose administration, only
2C‐EF‐FLY and two metabolites could be detected. The observed
elimination of water is probably attributed to the high temperature
in the injection port. After high dose administration, 2C‐T‐7‐FLY and
three of its metabolites could be detected and additionally one 2C‐
E‐FLY metabolite. Based on these data, it could not be stated whether
this metabolite was hydroxy 2C‐E‐FLY isomer 1 or 2 and therefore
whether it was a substance‐specific metabolite or not. Acetylation
during sample preparation resulted in the sum of acetylated parent
compound/metabolite and the corresponding, metabolically formed
N‐acetyl metabolite (M11, M18, M26, M27).
3.3.2 | LC−IT−MS SUSA
Results are summarized in Table 5. After low and high dose
administration, the three 2C‐FLY drugs and/or their metabolites could
be identified in rat urine based on the corresponding MS2 spectra. In
conclusion, an intake should be detectable by the LC‐IT‐MS SUSA.
3.3.3 | LC−HRMS/MS SUSA
Results are summarized inTable 6. Similar to the LC−IT−MS SUSA, the
three 2C‐FLY drugs and/or their metabolites could be identified in rat
urine after low and high dose administration by the corresponding
MS2 spectra. An intake is thus expected to be detectable by the LC
−HRMS/MS SUSA.
4 | CONCLUSIONS
In total, 32 metabolites of 2C‐E‐FLY, 2C‐EF‐FLY, and 2C‐T‐7‐FLY
could be identified in rat urine and in vitro incubations. Hydroxylation
and N‐acetylation were identified as main metabolic steps, whereas
methoxyamine was successfully used for detection of the deaminated
metabolites formed by MAO‐A and B. Most metabolites were identi-
fied in rat urine after precipitation. Phase I metabolic reactions were
mainly catalyzed by CYP2D6 and CYP3A4 and N‐acetylation by
NAT1 and NAT2. Intoxications with these NPS should be detectable
by all three tested SUSAs, but common metabolites of 2C‐E‐FLY and
2C‐EF‐FLY (M1, M8) have to be considered during interpretation of
analytical findings.
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TABLE 6 Toxicological detectability of 2C‐E‐FLY, 2C‐EF‐FLY, and 2C‐T‐7‐FLY in rat urine by the LC‐HRMS/MS standard urine screening
approach. Metabolite iDs correspond to Table 1. BW, body weight; −, not detected; D, precursor ion in MS1 detected; I, identified due to MS2
spectrum
Metabolite
iD
Parent
Compound or
Metabolite
Exact Precursor
Ion Mass, m/z
Retention
Time, Min
Administered
Dose, mg/kg BW
0.2 2
Parent compound 2C‐E‐FLY 234.1488 6.20 D I
M1 2C‐E‐FLY‐M (hydroxy) 250.1437 4.95 D I
M2 2C‐E‐FLY‐M (hydroxy) 250.1437 5.29 I I
M4 2C‐E‐FLY‐M (dihydroxy) 266.1386 4.50 D I
M5 2C‐E‐FLY‐M (dihydroxy) 266.1386 4.77 D I
M10 2C‐E‐FLY‐M (N‐acetyl) 276.1593 7.77 D I
M11 2C‐E‐FLY‐M (N‐acetyl hydroxy) 292.1543 6.14 D I
Parent compound 2C‐EF‐FLY 252.1394 5.80 I I
M15 2C‐EF‐FLY‐M (hydroxy) 268.1343 4.99 I I
M8 2C‐EF‐FLY‐M (carboxy) 264.1230 5.02 ‐ I
M18 2C‐EF‐FLY‐M (N‐acetyl) 294.1499 7.40 ‐ I
Parent compound 2C‐T‐7‐FLY 280.1365 6.88 ‐ I
M20 2C‐T‐7‐FLY‐M (sulfoxide) 296.1314 5.37 I I
M21 2C‐T‐7‐FLY‐M (hydroxy) 296.1314 5.55 D I
M24 2C‐T‐7‐FLY‐M (carboxy) 310.1107 5.70 D I
M27 2C‐T‐7‐FLY‐M (N‐acetyl sulfoxide) 338.1420 6.69 I I
M28 2C‐T‐7‐FLY‐M (N‐acetyl dihydroxy) 354.1369 5.65 I I
M29 2C‐T‐7‐FLY‐M (N‐acetyl carboxy) 352.1213 6.89 I I
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